Deciphering the actions of antiparkinsonian and antipsychotic drugs on cAMP/DARPP-32 signaling

Frontiers in Neuroanatomy

Volumn , Issue JULY, 2011, Pages

  Bonito Oliva, Alessandra ^a   Feyder, Michael ^a   Fisone, Gilberto ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

DARPP 32; Dopamine D1 receptor; Dopamine D2 receptor; ERK; Haloperidol; L DOPA; Medium spiny neurons

Indexed keywords

ANTIPARKINSON AGENT; CYCLIC AMP; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUTAMATE RECEPTOR 1; HALOPERIDOL; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROLEPTIC AGENT; PHOSPHOPROTEIN DARPP 32;

BRAIN NERVE CELL; CATALEPSY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDIATOR; MEDIUM SPINY NEURON; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 84863001043     PISSN: 16625129     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnana.2011.00038     Document Type: Review

References (106)

1. Adams, M. R., Brandon, E. P., Chartoff, E. H., Idzerda, R. L., Dorsa, D. M., and McKnight, G. S. (1997). Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 94, 12157-12161.
2. Albin, R. L., Young, A. B., and Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375.
3. Alexander, G. E., and Crutcher, M. D. (1990). Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13, 266-271.
4. Andersson, M., Hilbertson, A., and Cenci, M. A. (1999). Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6, 461-474.
5. Banke, T. G., Bowie, D., Lee, H., Huganir, R. L., Schousboe, A., and Traynelis, S. F. (2000). Control of GluR1 AMPA receptor function by cAMPdependent protein kinase. J. Neurosci. 20, 89-102.
6. Bateup, H. S., Santini, E., Shen, W., Birnbaum, S., Valjent, E., Surmeier, D. J., Fisone, G., Nestler, E. J., and Greengard, P. (2010). Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc. Natl. Acad. Sci. U.S.A. 107, 14845-14850.
7. Bateup, H. S., Svenningsson, P., Kuroiwa, M., Gong, S., Nishi, A., Heintz, N., and Greengard, P. (2008). Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat. Neurosci. 11, 932-939.
8. Berton, O., Guigoni, C., Li, Q., Bioulac, B. H., Aubert, I., Gross, C. E., Dileone, R. J., Nestler, E. J., and Bezard, E. (2009). Striatal overexpression of DeltaJunD resets lDOPA-induced dyskinesia in a primate model of Parkinson disease. Biol. Psychiatry 66, 554-561.
9. Bertran-Gonzalez, J., Bosch, C., Maroteaux, M., Matamales, M., Herve, D., Valjent, E., and Girault, J. A. (2008). Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J. Neurosci. 28, 5671-5685.
10. Bertran-Gonzalez, J., Hakansson, K., Borgkvist, A., Irinopoulou, T., Brami-Cherrier, K., Usiello, A., Greengard, P., Herve, D., Girault, J. A., Valjent, E., and Fisone, G. (2009). Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons. Neuropsychopharmacology 34, 1710-1720.
11. Birkmayer, W., and Hornykiewicz, O. (1998). The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat. Disord. 4, 59-60.
12. Blank, T., Nijholt, I., Teichert, U.,Kugler, H., Behrsing, H., Fienberg, A., Greengard, P., and Spiess, J. (1997). The phosphoprotein DARPP-32 mediates cAMPdependent potentiation of striatal N -methyl-d-aspartate responses. Proc. Natl. Acad. Sci. U.S.A. 94, 14859-14864.
13. Boyden, E. S., Zhang, F., Bamberg, E., Nagel, G., and Deisseroth, K. (2005). Millisecond-timescale, genetically targeted optical control of neural activity. Nat. Neurosci. 8, 1263-1268.
14. Braak, H., Del Tredici, K., Rub, U., De Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
15. Cadd, G., and McKnight, G. S. (1989). Distinct patterns of cAMP-dependent protein kinase gene expression in mouse brain. Neuron 3, 71-79.
16. Cao, X., Yasuda, T., Uthayathas, S., Watts, R. L., Mouradian, M. M., Mochizuki, H., and Papa, S. M. (2010). Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J. Neurosci. 30, 7335-7343.
17. Carta, A. R., Tronci, E., Pinna, A., and Morelli, M. (2005). Different responsiveness of striatonigral and striatopallidal neurons to l-DOPA after a subchronic intermittent lDOPA treatment. Eur. J. Neurosci. 21, 1196-1204.
18. Cenci, A. M., Whishaw, I. Q., and Schallert, T. (2002). Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. 3, 574-579.
19. Chen, J.-F., Moratalla, R., Impagnatiello, F., Grandy, D. K., Cuellar, B., Rubinstein, M., Beilstein, M. A., Hackett, E., Fink, S. J., Low, M. J., Ongini, E., and Schwarzschild, M. A. (2001). The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2A R)-mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 98, 1970-1975.
20. Cotzias, G. C., Van Woert, M. H., and Schiffer, L. M. (1967). Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276, 374-379.
21. Creese, I., Burt, D. R., and Snyder, S. H. (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of anti-schizophrenic drugs. Science 192, 481-483.
22. Darmopil, S., Martin, A. B., De Diego, I. R., Ares, S., and Moratalla, R. (2009). Genetic inactivation of dopamine D1 but not D2 receptors inhibits lDOPA-induced dyskinesia and histone activation. Biol. Psychiatry 66, 603-613.
23. Deisseroth, K. (2011). Optogenetics. Nat. Methods 8, 26-29.
24. DeLong, M. R. (1990). Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285.
25. Doucet, J. P., Nakabeppu, Y., Bedard, P. J., Hope, B. T., Nestler, E. J., Jasmin, B. J., Chen, J. S., Iadarola, M. J., St-Jean, M., Wigle, N., Blanchet, P., Grondin, R., and Robertson, G. S. (1996). Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur. J. Neurosci. 8, 365-381.
26. Dragunow, M., Robertson, G. S., Faull, R. L., Robertson, H. A., and Jansen, K. (1990). D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 37, 287-294.
27. Durieux, P. F., Bearzatto, B., Guiducci, S., Buch, T., Waisman, A., Zoli, M., Schiffmann, S. N., and De Kerchove d'Exaerde, A. (2009). D2R striatopallidal neurons inhibit both locomotor and drug reward processes. Nat. Neurosci. 12, 393-395.
28. Fasano, S., Bezard, E., D'Antoni, A., Francardo, V., Indrigo, M., Qin, L., Dovero, S., Cerovic, M., Cenci, M. A., and Brambilla, R. (2010). Inhibition of Ras-guanine nucleotidereleasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-dopainduced dyskinesia. Proc. Natl. Acad. Sci. U.S.A. 107, 21824-21829.
29. Fienberg, A. A., Hiroi, N., Mermelstein, P. G., Song, W., Snyder, G. L., Nishi, A., Cheramy, A., O'Callaghan, J. P., Miller, D. B., Cole, D. G., Corbett, R., Haile, C. N., Cooper, D. C., Onn, S. P., Grace, A. A., Ouimet, C. C., White, F. J., Hyman, S. E., Surmeier, D. J., Girault, J., Nestler, E. J., and Greengard, P. (1998). DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281, 838-842.
30. Fink, J. S., Weaver, D. R., Rivkees, S. A., Peterfreund, R. A., Pollack, A. E., Adler, E. M., and Reppert, S. M. (1992). Molecular cloning of the rat A2 adenosine receptor: selective coexpression with D2 dopamine receptor in rat striatum. Mol. Brain Res. 14, 186-195.
31. Fisone, G., Hakansson, K., Borgkvist, A., and Santini, E. (2007). Signaling in the basal ganglia: postsynaptic and presynaptic mechanisms. Physiol. Behav. 92, 8-14.
32. 2+ conductance. Neuroreport 8, 2183-2186.
33. Gao, T., Yatani, A., Dell'Acqua, M. L., Sako, H., Green, S. A., Dascal, N., Scott, J. D., and Hosey, M. M. (1997). cAMP-dependent regulation of cardiac L-type Ca2+ channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron 19, 185-196.
34. Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J. Jr., and Sibley, D. R. (1990). D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432.
35. Gerfen, C. R., Miyachi, S., Paletzki, R., and Brown, P. (2002). D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 22, 5042-5054.
36. Gerfen, C. R., Paletzki, R., and Worley, P. (2008). Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamineand cAMPregulated phosphoprotein-32 to activation of extracellular signalregulated kinase. J. Neurosci. 28, 7113-7120.
37. Glatt, C. E., and Snyder, S. H. (1993). Cloning and expression of an adenylyl cyclase localized to the corpus striatum. Nature 361, 536-538.
38. Goetz, C. G., Poewe, W., Rascol, O., and Sampaio, C. (2005). Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov. Disord. 20, 523-539.
39. Gong, S., Doughty, M., Harbaugh, C. R., Cummins, A., Hatten, M. E., Heintz, N., and Gerfen, C. R. (2007). Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs. J. Neurosci. 27, 9817-9823.
40. Gong, S., Zheng, C., Doughty, M. L., Losos, K., Didkovsky, N., Schambra, U. B., Nowak, N. J., Joyner, A., Leblanc, G., Hatten, M. E., and Heintz, N. (2003). A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425, 917-925.
41. Greengard, P. (2001). The neurobiology of slow synaptic transmission. Science 294, 1024-1030.
42. Greif, G. J., Lin, Y. J., Liu, J. C., and Freedman, J. E. (1995). Dopaminemodulated potassium channels on rat striatal neurons: specific activation and cellular expression. J. Neurosci. 15, 4533-4544.
43. Guigoni, C., Aubert, I., Li, Q., Gurevich, V. V., Benovic, J. L., Ferry, S., Mach, U., Stark, H., Leriche, L., Hakansson, K., Bioulac, B. H., Gross, C. E., Sokoloff, P., Fisone, G., Gurevich, E. V., Bloch, B., and Bezard, E. (2005). Pathogenesis of levodopainduced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat. Disord. 11(Suppl. 1), S25-S29.
44. Håkansson, K., Galdi, S., Hendrick, J., Snyder, G., Greengard, P., and Fisone, G. (2006). Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J. Neurochem. 96, 482-488.
45. Håkansson, K., Pozzi, L., Usiello, A., Haycock, J., Borrelli, E., and Fisone, G. (2004). Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol. Eur. J. Neurosci. 20, 1108-1112.
46. Heintz, N. (2001). BAC to the future: the use of bac transgenic mice for neuroscience research. Nat. Rev. Neurosci. 2, 861-870.
47. Hemmings, H. C. Jr., Greengard, P., Tung, H. Y., and Cohen, P. (1984). DARPP-32, a dopamineregulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310, 503-505.
48. Hernandez-Lopez, S., Tkatch, T., PerezGarci, E., Galarraga, E., Bargas, J., Hamm, H., and Surmeier, D. J. (2000). D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1IP3-calcineurin-signaling cascade. J. Neurosci. 20, 8987-8995.
49. Herve, D., Le Moine, C., Corvol, J. C., Belluscio, L., Ledent, C., Fienberg, A. A., Jaber, M., Studler, J. M., and Girault, J. A. (2001). Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J. Neurosci. 21, 4390-4399.
50. Hope, B. T., Nye, H. E., Kelz, M. B., Self, D. W., Iadarola, M. J., Nakabeppu, Y., Duman, R. S., and Nestler, E. J. (1994). Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 13, 1235-1244.
51. Hopf, F. W., Cascini, M. G., Gordon, A. S., Diamond, I., and Bonci, A. (2003). Cooperative activation of dopamine D1 and D2 receptors increases spike firing of nucleus accumbens neurons via G-protein betagamma subunits. J. Neurosci. 23, 5079-5087.
52. Hornykiewicz, O. (1963). Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der Substantia nigra des normalen und Parkinsonkranken Menschen. Wien. Klin. Wochenschr. 56, 426-427.
53. Kebabian, J. W., and Calne, D. B. (1979). Multiple receptors for dopamine. Nature 277, 93-96.
54. Kitai, S. T., and Surmeier, D. J. (1993). Cholinergic and dopaminergic modulation of potassium conductances in neostriatal neurons. Adv. Neurol. 60, 40-52.
55. Konradi, C., and Heckers, S. (1995). Haloperidol-induced Fos expression in striatum is dependent upon transcription factor cyclic AMP response element binding protein. Neuroscience 65, 1051-1061.
56. Kravitz, A. V., Freeze, B. S., Parker, P. R., Kay, K., Thwin, M. T., Deisseroth, K., and Kreitzer, A. C. (2010). Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466, 622-626.
57. Kull, B., Svenningsson, P., and Fredholm, B. B. (2000). Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum. Mol. Pharmacol. 58, 771-777.
58. Kuzhikandathil, E. V., Yu, W., and Oxford, G. S. (1998). Human dopamine D3 and D2L receptors couple to inward rectifier potassium channels in mammalian cell lines. Mol. Cell. Neurosci. 12, 390-402.
59. Lebel, M., Chagniel, L., Bureau, G., and Cyr, M. (2010). Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol. Dis. 38, 59-67.
60. Li, J., Guo, Y., Schroeder, F. A., Youngs, R. M., Schmidt, T. W., Ferris, C., Konradi, C., and Akbarian, S. (2004). Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. J. Neurochem. 90, 1117-1131.
61. Liu, J. C., Defazio, R. A., Espinosa-Jeffrey, A., Cepeda, C., De Vellis, J., and Levine, M. S. (2004). Calcium modulates dopamine potentiation of N -methyl-d-aspartate responses: electrophysiological and imaging evidence. J. Neurosci. Res. 76, 315-322.
62. MacGibbon, G. A., Lawlor, P. A., Bravo, R., and Dragunow, M. (1994). Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Brain Res. Mol. Brain Res. 23, 21-32.
63. MacGibbon, G. A., Lawlor, P. A., Hughes, P., Young, D., and Dragunow, M. (1995). Differential expression of inducible transcription factors in basal ganglia neurons. Brain Res. Mol. Brain Res. 34, 294-302.
64. Mangiavacchi, S., and Wolf, M. E. (2004). D1 dopamine receptor stimulation increases the rate of AMPA receptor insertion onto the surface of cultured nucleus accumbens neurons through a pathway dependent on protein kinase A. J. Neurochem. 88, 1261-1271.
65. Mattingly, R. R. (1999). Phosphorylation of serine 916 of Ras-GRF1 contributes to the activation of exchange factor activity by muscarinic receptors. J. Biol. Chem. 274, 37379-37384.
66. Miller, J. C. (1990). Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J. Neurochem. 54, 1453-1455.
67. Miyamoto, S., Duncan, G. E., Marx, C. E., and Lieberman, J. A. (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79-104.
68. Mons, N., and Cooper, D. M. (1994). Selective expression of one Ca(2+) inhibitable adenylyl cyclase in dopaminergically innervated rat brain regions. Brain Res. Mol. Brain Res. 22, 236-244.
69. Nestler, E. J., Barrot, M., and Self, D. W. (2001). DeltaFosB: a sustained molecular switch for addiction. Proc. Natl. Acad. Sci. U.S.A. 98, 11042-11046.
70. Nishi, A., Snyder, G. L., and Greengard, P. (1997). Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17, 8147-8155.
71. Nowak, S. J., and Corces, V. G. (2004). Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet. 20, 214-220.
72. Obeso, J. A., Olanow, C. W., and Nutt, J. G. (2000). Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23, S2-S7.
73. Parr-Brownlie, L. C., and Hyland, B. I. (2005). Bradykinesia induced by dopamine D2 receptor blockade is associated with reduced motor cortex activity. J. Neurosci. 25, 5700-5709.
74. Pavon, N., Martin, A. B., Mendialdua, A., and Moratalla, R. (2006). ERK phosphorylation and FosB expression are associated with l-DOPAinduced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 59, 64-74.
75. Picconi, B., Centonze, D., Hakansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., and Calabresi, P. (2003). Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 6, 501-506.
76. Pozzi, L., Hakansson, K., Usiello, A., Borgkvist, A., Lindskog, M., Greengard, P., and Fisone, G. (2003). Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J. Neurochem. 86, 451-459.
77. Robertson, G. S., and Fibiger, H. C. (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46, 315-328.
78. Robertson, G. S., Vincent, S. R., and Fibiger, H. C. (1992). D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience 49, 285-296.
79. Robinson, S. W., and Caron, M. G. (1997). Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol. Pharmacol. 52, 508-514.
80. Roche, K. W., O'Brien, R. J., Mammen, A. L., Bernhardt, J., and Huganir, R. L. (1996). Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16, 1179-1188.
81. Santini, E., Alcacer, C., Cacciatore, S., Heiman, M., Herve, D., Greengard, P., Girault, J. A., Valjent, E., and Fisone, G. (2009). l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigralmediumspinyneuronsof hemiparkinsonian mice. J. Neurochem. 108, 621-633.
82. Santini, E., Sgambato-Faure, V., Li, Q., Savasta, M., Dovero, S., Fisone, G., and Bezard, E. (2010). Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in l-DOPA-induced dyskinesia. PLoS ONE 5, e12322. doi: 10.1371/journal.pone.0012322
83. Santini, E., Valjent, E., and Fisone, G. (2008). Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J. 275, 1392-1399.
84. Santini, E., Valjent, E., Usiello, A., Carta, M., Borgkvist, A., Girault, J. A., Herve, D., Greengard, P., and Fisone, G. (2007). Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA-induced dyskinesia. J. Neurosci. 27, 6995-7005.
85. Schiffmann, S. N., Jacobs, O., and Vanderhaegen, J. J. (1991). Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57, 1062-1067.
86. Schuster, S., Nadjar, A., Guo, J. T., Li, Q., Ittrich, C., Hengerer, B., and Bezard, E. (2008). The 3-hydroxy3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of l-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J. Neurosci. 28, 4311-4316.
87. Seeman, P., Lee, T., Chau-Wong, M., and Wong, K. (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717-719.
88. Snyder, G. L., Allen, P. B., Fienberg, A. A., Valle, C. G., Huganir, R. L., Nairn, A. C., and Greengard, P. (2000). Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. J. Neurosci. 20, 4480-4488.
89. Snyder, G. L., Fienberg, A. A., Huganir, R. L., and Greengard, P. (1998). A dopamine/D1 receptor/protein kinase A/dopamineand cAMPregulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J. Neurosci. 18, 10297-10303.
90. Stipanovich, A., Valjent, E., Matamales, M., Nishi, A., Ahn, J. H., Maroteaux, M., Bertran-Gonzalez, J., BramiCherrier, K., Enslen, H., Corbille, A. G., Filhol, O., Nairn, A. C., Greengard, P., Herve, D., and Girault, J. A. (2008). A phosphatase cascade by which rewarding stimuli control nucleosomal response. Nature 453, 879-884.
91. Stoof, J. C., and Kebabian, J. W. (1981). Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294, 366-368.
92. Surmeier, D. J., Bargas, J., Hemmings, H. C. Jr., Nairn, A. C., and Greengard, P. (1995). Modulation of calcium currents by a D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron 14, 385-397.
93. Surmeier, D. J., Ding, J., Day, M., Wang, Z., and Shen, W. (2007). D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 30, 228-235.
94. Svenningsson, P., Lindskog, M., Ledent, C., Parmentier, M., Greengard, P., Fredholm, B. B., and Fisone, G. (2000). Regulation of the phosphorylation of the dopamineand cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc. Natl. Acad. Sci. U.S.A. 97, 1856-1860.
95. Svenningsson, P., Lindskog, M., Rognoni, F., Fredholm, B. B., Greengard, P., and Fisone, G. (1998). Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 84, 223-228.
96. Tekumalla, P. K., Calon, F., Rahman, Z., Birdi, S., Rajput, A. H., Hornykiewicz, O., Di Paolo, T., Bedard, P. J., and Nestler, E. J. (2001). Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol. Psychiatry 50, 813-816.
97. Thomas, G. M., and Huganir, R. L. (2004). MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci. 5, 173-183.
98. Thomson, S., Clayton, A. L., Hazzalin, C. A., Rose, S., Barratt, M. J., and Mahadevan, L. C. (1999). The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J. 18, 4779-4793.
99. Valjent, E., Bertran-Gonzalez, J., Herve, D., Fisone, G., and Girault, J. A. (2009). Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice. Trends Neurosci. 32, 538-547.
100. Valjent, E., Corvol, J. C., Pages, C., Besson, M. J., Maldonado, R., and Caboche, J. (2000). Involvement of the extracellular signalregulated kinase cascade for cocainerewarding properties. J. Neurosci. 20, 8701-8709.
101. Valjent, E., Pascoli, V., Svenningsson, P., Paul, S., Enslen, H., Corvol, J. C., Stipanovich, A., Caboche, J., Lombroso, P. J., Nairn, A. C., Greengard, P., Herve, D., and Girault, J. A. (2005). Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U.S.A. 102, 491-496.
102. Westin, J. E., Vercammen, L., Strome, E. M., Konradi, C., and Cenci, M. A. (2007). Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 62, 800-810.
103. Wickens, J. R., and Wilson, C. J. (1998). Regulation of action-potential firing in spiny neurons of the rat neostriatum in vivo. J. Neurophysiol. 79, 2358-2364.
104. Wickman, K. D., Iniguez-Lluhl, J. A., Davenport, P. A., Taussig, R., Krapivinsky, G. B., Linder, M. E., Gilman, A. G., and Clapham, D. E. (1994). Recombinant Gprotein beta gamma-subunits activate the muscarinic-gated atrial potassium channel. Nature 368, 255-257.
105. Xie, G. Q., Wang, S. J., Li, J., Cui, S. Z., Zhou, R., Chen, L., and Yuan, X. R. (2009). Ethanol attenuates the HFS-induced, ERK-mediated LTP in a dose-dependent manner in rat striatum. Alcohol. Clin. Exp. Res. 33, 121-128.
106. Zhuang, X., Belluscio, L., and Hen, R. (2000). G(olf)alpha mediates dopamine D1 receptor signaling. J. Neurosci. 20, RC91.